...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control

My guess is that they hope for better results by dropping the androgen-deprived therapy and adding the BET Bromodomain Inhibitor ZEN-3694.

I hope that's true as well.

Given that the ZEN study also includes both Enzalutamide and Pembrolizumab, why are similar side effects not a possible concern in the ZEN study?

 

Share
New Message
Please login to post a reply